Liying Xue
Shijiazhuang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.
Journal: Frontiers in oncology
Published: November 11, 2025
Case report and literature review: Golidocitinib as a potential treatment for monomorphic epitheliotropic intestinal T-cell lymphoma.
Journal: Frontiers in oncology
Published: October 21, 2025
Correlates and Consequences of Clonal Hematopoiesis Expansion Rate: A 15-Year Longitudinal Study of 6,986 Women.
Journal: medRxiv : the preprint server for health sciences
Published: January 27, 2025
Rituximab in Immune-mediated thrombotic thrombocytopenic purpura.
Journal: European journal of internal medicine
Published: December 06, 2024
Comprehensive analysis of CMTM family and immune infiltration in esophageal carcinoma.
Journal: PloS one
Published: November 06, 2024
Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment.
Journal: Frontiers in medicine
Published: April 30, 2024
CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review.
Journal: Cancer management and research
Published: January 18, 2022
A novel variant of SLC4A1 for hereditary spherocytosis in a Chinese family: a case report and systematic review.
Journal: BMC medical genomics
Published: September 28, 2021
Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
Journal: Molecular medicine reports
Published: May 18, 2020
Trefoil factor 1 and gastrokine 2 inhibit Helicobacter pylori-induced proliferation and inflammation in gastric cardia and distal carcinogenesis.
Journal: Oncology letters
Published: April 15, 2020
Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.
Journal: Oncology letters
Published: October 15, 2018
Last Updated: 09/26/2026